| Literature DB >> 27830534 |
Rogério da Rosa Gerbatin1, Gustavo Cassol2, Fernando Dobrachinski3, Ana Paula O Ferreira2, Caroline B Quines4, Iuri D Della Pace2, Guilherme L Busanello2, Jessié M Gutierres3, Cristina W Nogueira4, Mauro S Oliveira5, Félix A Soares3, Vera M Morsch3, Michele R Fighera2,6, Luiz Fernando F Royes2.
Abstract
Traumatic brain injury (TBI) is one of the most common types of brain injuries that cause death or persistent neurological disturbances in survivors. Most of the promising experimental drugs were not effective in clinical trials; therefore, the development of TBI drugs represents a huge unmet need. Guanosine, an endogenous neuroprotective nucleoside, has not been evaluated in TBI to the best of our knowledge. Therefore, the present study evaluated the effect of guanosine on TBI-induced neurological damage. Our findings showed that a single dose of guanosine (7.5 mg/kg, intraperitoneally (i.p.) injected 40 min after fluid percussion injury (FPI) in rats protected against locomotor and exploratory impairments 8 h after injury. The treatment also protected against neurochemical damage to the ipsilateral cortex, glutamate uptake, Na+/K+-ATPase, glutamine synthetase activity, and alterations in mitochondrial function. The inflammatory response and brain edema were also reduced by this nucleoside. In addition, guanosine protected against neuronal death and caspase 3 activation. Therefore, this study suggests that guanosine plays a neuroprotective role in TBI and can be exploited as a new pharmacological strategy.Entities:
Keywords: Fluid percussion injury; Glutamate; Motor deficit; Neuroprotection; Neurotoxicity; Nucleoside
Mesh:
Substances:
Year: 2016 PMID: 27830534 DOI: 10.1007/s12035-016-0238-z
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590